MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Bronchogen Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Bronchogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu, AEDL; about 446.5 Da) from Vladimir Khavinson's short-peptide program, patented as a substance restoring respiratory-organ function. Rather than acting on a surface receptor, it is hypothesized to enter the nucleus of bronchial and alveolar cells and bind DNA promoter sequences, raising local DNA thermostability and modulating genes tied to respiratory epithelial differentiation, surfactant production, and local immunity (PMID 25015171, 21240358). In rat models of obstructive lung pathology, a one-month course reduced COPD-type airway remodeling, restored ciliated cells, and increased secretory IgA (PMID 26468022, 30199201). It is used in research as an oral capsule (about 200-400 mcg/day) or as an injectable from a 20 mg vial in short 10-day courses. No human clinical trials exist, and Bronchogen is not approved by the FDA or EMA; it is a research and educational compound only.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 1-2 mg/day SC (10-day courses)
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Lyophilized vial: store at -20 °C long term, or 2-8 °C for short periods, protected from light. Once reconstituted, keep refrigerated at 2-8 °C and use within about 3-4 weeks.
Half-life: Not formally measured; as a small unmodified tetrapeptide it is expected to be cleared from plasma within minutes, with effects attributed to downstream gene expression.
Route: Oral capsule (~200-400 mcg/day) or injection clinically/in research; modeled here as a subcutaneous reconstitution reference from a 20 mg vial.
Status: Not FDA or EMA approved; sold for laboratory research and educational use only.
About Bronchogen
Bronchogen is a respiratory-targeted Khavinson bioregulator (the tetrapeptide Ala-Glu-Asp-Leu, AEDL) studied for its proposed ability to normalize gene expression in bronchial and alveolar tissue [1][2]. In the original Russian gerontology framework these short peptides were given as oral capsules (the "Cytogen" line, roughly 200-400 mcg/day) and as parenteral lyophilized preparations; clinically and in the founding animal studies the route was oral or intramuscular/intraperitoneal injection, so the subcutaneous figures below are an educational reconstitution reference modeled on the 20 mg injectable vial sold for research, not a validated clinical regimen [1]. No human trials of Bronchogen have been published, so every dose here is illustrative only.\n\nEducational guide for Bronchogen reconstitution and short-course dosing.\n\nFrequency: Inject once daily subcutaneously during a short course of roughly 10 days (some bioregulator protocols run 10-30 days), with courses typically repeated two to three times per year [3]. Reconstituting a 20 mg vial with 2 mL of bacteriostatic water yields 10 mg/mL, so a 1-2 mg daily dose corresponds to 10-20 units on a U-100 insulin syringe.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe.
Inject it slowly down the inner wall of the 20 mg Bronchogen vial; do not spray it directly onto the lyophilized powder.
Gently swirl or roll the vial until the powder fully dissolves into a clear, colorless solution; never shake, which can shear the peptide and cause foaming.
The result is 10 mg/mL, so 1 mg is 10 units (0.1 mL) and 2 mg is 20 units (0.2 mL) on a U-100 insulin syringe; swab the stopper and draw your daily dose.
Inject subcutaneously once daily during the course, store the vial refrigerated at 2-8 °C between uses, and discard after the stability window (about 3-4 weeks).
Interactive Bronchogen Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Conservative course (days 1-10) | 1000 mcg (1 mg) | 10 units (0.10 mL) |
| Standard course (days 1-10) | 2000 mcg (2 mg) | 20 units (0.20 mL) |
| Seasonal repeat (2-3x per year) | 2000 mcg (2 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Bronchogen, 20 mg each):
- checkOne 10-day course at the standard 2 mg/day uses a full 20 mg vial (a 1 mg/day course uses about half a vial).
- check8-week window (about 2 short courses): 2 vials.
- check12-week window (about 3 short courses): 3 vials.
- check16-week window (about 4 short courses): 4 vials.
Insulin Syringes (U-100):
- checkOne 0.3 mL (30-unit) syringe per daily injection, about 10 per 10-day course.
- check8-week window: roughly 20 syringes.
- check12-week window: roughly 30 syringes.
- check16-week window: roughly 40 syringes.
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- checkOne 30 mL bottle reconstitutes up to 15 vials, so a single bottle covers a typical 8-16 week plan.
- check8-week window (2 vials): about 4 mL, one bottle.
- check12-week window (3 vials): about 6 mL, one bottle.
- check16-week window (4 vials): about 8 mL, one bottle.
Alcohol Swabs:
- checkUse one swab for the vial stopper and one for the skin at each injection.
- check8-week window: roughly 40 swabs.
- check12-week window: roughly 60 swabs.
- check16-week window: roughly 80 swabs.
Mechanism of Action (MOA)
Bronchogen is the trade name for the synthetic tetrapeptide Ala-Glu-Asp-Leu (AEDL; molecular weight about 446.5 Da), one of the tissue-specific "cytogen" short peptides developed within Vladimir Khavinson's bioregulation framework at the St. Petersburg Institute of Bioregulation and Gerontology and patented as a substance "restoring respiratory organs function" [1][8]. Like the other Khavinson di-, tri-, and tetrapeptides, it is not thought to act on a cell-surface receptor. Instead, the prevailing hypothesis is that the peptide is small and charged enough to cross the cell and nuclear membranes, bind specific nucleotide motifs in gene promoter regions, and modulate transcription of a defined set of genes rather than supplying a classical signaling ligand [2][7].\n\nBiophysical work supports a direct nucleic-acid interaction: calorimetry showed that AEDL binds DNA and raises its melting temperature by roughly 3 °C, increasing local double-helix thermostability in a sequence-influenced way [4]. In cultured human bronchial epithelial cells, AEDL increased expression of respiratory differentiation and surfactant-related genes (reported to include NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2) and stimulated protein synthesis, consistent with the proposed epigenetic-style regulatory mechanism [2].\n\nThe sequence is reported to be selective for bronchopulmonary tissue. In rat models of chronic obstructive lung pathology, a one-month course of AEDL reduced the airway remodeling typical of COPD: goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration, and emphysematous change diminished while ciliated cells were restored. Production of secretory IgA, a marker of local airway immunity, rose, and the cell composition and proinflammatory cytokine profile of the bronchoalveolar space normalized, reflecting reduced neutrophilic inflammation [3][5]. At the class level, Khavinson peptides have been described as stimulating tissue-specific cell differentiation, including during cellular aging [6].\n\nPharmacokinetics have not been formally characterized for Bronchogen. As a small, unmodified tetrapeptide it is expected to be rapidly hydrolyzed by plasma and tissue peptidases, giving a free-peptide plasma half-life on the order of minutes; any sustained effect is attributed to downstream changes in gene expression rather than to continued presence of the intact peptide. Oral bioavailability of such peptides is low because of gastrointestinal proteolysis, which is why the Russian Cytogen products use capsules and why injectable lyophilized vials are also marketed.\n\nHistorically these bioregulators were delivered as oral capsules (about 200-400 mcg/day) or by intramuscular/intraperitoneal injection in short seasonal courses; the original patent examples used intraperitoneal and intramuscular dosing in animals (a therapeutic dose near 0.2 mcg/kg) with parenteral solutions in saline or sterile water [1]. The once-daily subcutaneous reconstitution described on this page is an educational modeling convention, not a route validated for Bronchogen. Reconstituting a 20 mg vial in 2 mL of bacteriostatic water gives 10 mg/mL, so a 1-2 mg dose corresponds to 10-20 units on a U-100 syringe. Bronchogen remains an unapproved research compound, and the dosing here should be read as reference information only, not therapeutic guidance.
Clinical Trial Efficacy Highlights
- starThe foundational US patent (US 7,625,870 B2, Khavinson, Ryzhak, Grigoriev, and Ryadnova, titled "Peptide substance restoring respiratory organs function") describes the AEDL tetrapeptide restoring respiratory-organ function in animal examples and forms the original basis for Bronchogen's pulmonary claims; the documented routes were intraperitoneal and intramuscular, with a therapeutic dose near 0.2 mcg/kg [1].
- starKhavinson and colleagues (2014, Lung) reported that AEDL regulates gene expression and protein synthesis in bronchial epithelium, increasing expression of differentiation- and surfactant-associated genes in cultured human bronchial epithelial cells and supporting the proposed DNA-promoter mechanism [2].
- starKuzubova and colleagues (2015, Bulletin of Experimental Biology and Medicine) found that a one-month course of the bronchial tetrapeptide in rats with experimental obstructive lung pathology reduced goblet-cell hyperplasia, squamous metaplasia, and lymphocytic infiltration, restored ciliated cells, and raised secretory IgA, indicating normalized bronchial-epithelium function [3].
- starMonaselidze and colleagues (2011, Bulletin of Experimental Biology and Medicine) used differential scanning calorimetry to show that bronchogen binds DNA and increases its thermostability (melting temperature rose by roughly 3 °C), providing biophysical evidence for the direct peptide-DNA interaction invoked as its mechanism [4].
- starTitova and colleagues (2017, Russian Journal of Physiology) reported an antiinflammatory and regenerative effect of peptide therapy in a model of obstructive lung pathology, with reduced neutrophilic inflammation and normalization of proinflammatory cytokines in the bronchoalveolar space [5].
- starKhavinson and colleagues (2012, Bulletin of Experimental Biology and Medicine) showed that short Khavinson peptides tissue-specifically stimulate cell differentiation, including in aging cell cultures, providing class-level support for the differentiation-promoting actions attributed to AEDL [6].
- starA 2021 systematic review in Molecules summarizing the Khavinson short-peptide program describes how 2-7 residue peptides regulate tissue-specific gene expression and protein synthesis; it provides the mechanistic rationale for AEDL but reports no human efficacy data [7].
- starKhavinson's overarching "Peptides and Ageing" review lays out the tissue-specific geroprotector framework under which Bronchogen was designed, but it presents AEDL as a preclinical respiratory analogue rather than a clinically validated therapy [8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNo controlled human safety data exist for Bronchogen; its adverse-effect profile is unknown, and the points below are extrapolated from injectable peptides and the Khavinson bioregulator class generally.
- warningSubcutaneous injection can cause local reactions including redness, itching, swelling, bruising, or transient pain at the injection site.
- warningAny injected peptide carries a theoretical risk of immune or hypersensitivity reactions; stop use and seek care for rash, hives, facial or throat swelling, wheezing, or difficulty breathing.
- warningResearch-grade peptides are not manufactured to pharmaceutical standards, so contamination, endotoxin, incorrect sequence, or inaccurate vial content are realistic risks; sterility and purity cannot be assumed.
- warningThere are no drug-interaction studies; people taking respiratory medications (inhaled corticosteroids, bronchodilators), anticoagulants, or other drugs should not assume Bronchogen is inert or compatible, and it is not a substitute for prescribed asthma or COPD therapy.
- warningBronchogen has not been evaluated in pregnancy, breastfeeding, in children, or in people with active lung disease, and should be avoided in these groups.
- warningBecause the proposed mechanisms involve modulating cell proliferation, differentiation, and gene expression, long-term and oncologic safety is entirely uncharacterized.
- warningRegulatory status: Bronchogen is not approved by the FDA, EMA, or any major regulator as a drug; it is sold for laboratory research only and is not a dietary supplement or medicine.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Bronchogen dosage?expand_more
There is no clinically validated dose, because Bronchogen has never been tested in published human trials. In bioregulator and supplier protocols the typical injectable Bronchogen dosage is about 1-2 mg per day from a 20 mg lyophilized vial, given in short courses of roughly 10 days (some protocols extend to 10-30 days) and repeated two to three times per year. The oral "Cytogen" capsule form is marketed at about 200-400 mcg/day. The subcutaneous figures on this page are an educational reconstitution reference only, not medical advice.
Is Bronchogen FDA approved?expand_more
No. Bronchogen is not approved by the FDA, the EMA, or any other major regulator for any indication. It originates from the Russian Khavinson peptide-bioregulator program (US Patent 7,625,870) and is sold only for laboratory research. It is not a medicine or a dietary supplement, and it is not a substitute for prescribed asthma or COPD treatment.
How do you reconstitute Bronchogen?expand_more
For the educational subcutaneous model on this page, draw 2 mL of bacteriostatic water and add it slowly down the inner wall of the 20 mg vial, then swirl gently until fully dissolved. That yields 10 mg/mL, so 1 mg equals 10 units (0.1 mL) and 2 mg equals 20 units (0.2 mL) on a U-100 insulin syringe. Keep the reconstituted vial refrigerated at 2-8 °C and use it within about 3-4 weeks. Note that the original research used oral capsules and intramuscular or intraperitoneal injection rather than subcutaneous dosing.
What is the half-life of Bronchogen?expand_more
Bronchogen's half-life has not been formally measured. As a small, unmodified tetrapeptide (Ala-Glu-Asp-Leu, about 446.5 Da) it is expected to be hydrolyzed by plasma and tissue peptidases within minutes. The proposed durable effects come from downstream changes in gene expression rather than from the intact peptide persisting in circulation, which is why protocols use short repeated courses instead of continuous dosing.
Can Bronchogen be stacked with other Khavinson peptides?expand_more
In the bioregulator literature, tissue-specific cytogens such as Bronchogen are sometimes run alongside other Khavinson peptides on the theory that each targets a different organ system. However, there are no controlled studies of any such combination, no interaction or safety data, and no human efficacy evidence. Any stacking is purely experimental and outside validated medical practice.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Bronchogen, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VKh, Ryzhak GA, Grigoriev EI, Ryadnova IYu. Peptide substance restoring respiratory organs function (tetrapeptide Ala-Glu-Asp-Leu). United States Patent US 7,625,870 B2; granted December 1, 2009. View Scientific Paper →
Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. View Scientific Paper →
Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015;159(5):685-688. View Scientific Paper →
Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-377. View Scientific Paper →
Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV. [Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology]. Ross Fiziol Zh Im I M Sechenova. 2017;103(2):201-208. View Scientific Paper →
Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →